OBJECTIVE: To examine African-American prostate cancer (PCa) survivors' involvement in treatment decision-making (TDM), and examine the association between TDM and quality of life (QOL), using secondary data. METHODS: African-American PCa survivors (181) were recruited from the North Carolina Central Cancer Registry. Participants completed a cross-sectional survey that asked about their chosen cancer treatment, TDM factors, and PCa-specific QOL (using the Expanded Prostate Cancer Index Composite--EPIC). Multivariate analysis of covariance was conducted to determine the association between TDM and QOL, controlling for confounders. RESULTS: Most men reported being active (44.2%) or collaborative (38.1%) in TDM, while 14.4% preferred a passive role. Adjusting for marital status, education and treatment, passive patients reported somewhat better QOL compared to active patients in the following QOL domains: urinary summary (p=0.04), urinary function (p=0.01), and urinary incontinence (p=0.03). CONCLUSION: Most African-American PCa survivors preferred to be, and were, actively or collaboratively involved in TDM. However, those who preferred a passive role reported better PCa-specific QOL for the urinary domain compared to others. PRACTICE IMPLICATIONS: It is important to assess patients' TDM preference. Patients' QOL may differ by their TDM role, such that active patients may be more bothered by treatment side effects than other patients.
OBJECTIVE: To examine African-American prostate cancer (PCa) survivors' involvement in treatment decision-making (TDM), and examine the association between TDM and quality of life (QOL), using secondary data. METHODS: African-American PCa survivors (181) were recruited from the North Carolina Central Cancer Registry. Participants completed a cross-sectional survey that asked about their chosen cancer treatment, TDM factors, and PCa-specific QOL (using the Expanded Prostate Cancer Index Composite--EPIC). Multivariate analysis of covariance was conducted to determine the association between TDM and QOL, controlling for confounders. RESULTS: Most men reported being active (44.2%) or collaborative (38.1%) in TDM, while 14.4% preferred a passive role. Adjusting for marital status, education and treatment, passive patients reported somewhat better QOL compared to active patients in the following QOL domains: urinary summary (p=0.04), urinary function (p=0.01), and urinary incontinence (p=0.03). CONCLUSION: Most African-American PCa survivors preferred to be, and were, actively or collaboratively involved in TDM. However, those who preferred a passive role reported better PCa-specific QOL for the urinary domain compared to others. PRACTICE IMPLICATIONS: It is important to assess patients' TDM preference. Patients' QOL may differ by their TDM role, such that active patients may be more bothered by treatment side effects than other patients.
Authors: Lisa C Campbell; Francis J Keefe; Cindy Scipio; Daphne C McKee; Christopher L Edwards; Steven H Herman; Lawrence E Johnson; O Michael Colvin; Colleen M McBride; Craig Donatucci Journal: Cancer Date: 2007-01-15 Impact factor: 6.860
Authors: Clement K Gwede; Julio Pow-Sang; John Seigne; Randy Heysek; Mohamed Helal; Kristin Shade; Alan Cantor; Paul B Jacobsen Journal: Cancer Date: 2005-10-01 Impact factor: 6.860
Authors: Barbara D Powe; Jill Hamilton; Nichole Hancock; Natasha Johnson; Ramona Finnie; Jean Ko; Patrice Brooks; Maurice Boggan Journal: Cancer Date: 2007-01-15 Impact factor: 6.860
Authors: Sascha M Keij; Joyce E de Boer; Anne M Stiggelbout; Wändi Bruine de Bruin; Ellen Peters; Saïda Moaddine; Marleen Kunneman; Arwen H Pieterse Journal: BMJ Open Date: 2022-05-24 Impact factor: 3.006
Authors: Mohsen Bazargan; James L Smith; Paul Robinson; John Uyanne; Ruqayyah Abdulrahoof; Chika Chuku; Shervin Assari Journal: Int J Environ Res Public Health Date: 2019-05-17 Impact factor: 3.390
Authors: Linda Brom; Wendy Hopmans; H Roeline W Pasman; Danielle R M Timmermans; Guy A M Widdershoven; Bregje D Onwuteaka-Philipsen Journal: BMC Med Inform Decis Mak Date: 2014-04-03 Impact factor: 2.796
Authors: Nynikka R Palmer; Janet K Shim; Celia P Kaplan; Dean Schillinger; Sarah D Blaschko; Benjamin N Breyer; Rena J Pasick Journal: BMJ Open Date: 2020-08-05 Impact factor: 2.692